Off the back of its $74 billion acquisition of Celgene, Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted its biologics license application (BLA) for its CAR-T treatment priority review. This means a decision will come as soon as August 17, 2020, which is four months earlier than it would have under the standard review process. Similar to other CAR-T therapies, liso-cel involves taking immune cells and manipulating them so they target lymphoma cells expressing proteins consistent with blood cancer, like CD19. Currently, liso-cel is an investigational compound that is not approved for use in any country. Bristol-Myers acquired liso-cel through its procurement of Celgene, though the treatment was originally developed by the biotech firm, Juno Therapeutics which it acquired in 2018. Bristol-Myers currently has a number of CAR-T therapies as well as others that involve a similar technique using the T-cell receptor to target tumor cells.